Program Description
Though targeted therapies such as Bruton tyrosine kinase (BTK) and BCL-2 inhibitors have improved outcomes in chronic lymphocytic leukemia (CLL), challenges remain. Real-world data indicate high rates of discontinuation due to BTK inhibitor resistance or intolerance due to treatment-related adverse effects. These treatment effects limit medication adherence, which contributes to higher health care utilization costs. This virtual symposium will review the current treatment approaches for CLL, highlighting new dosing strategies, recent updates in treatment guidelines, and the managed care pharmacist's perspective on operational and financial challenges to optimizing coordination of care. Panelists will discuss continuous- and fixed-duration treatment regimens, with a focus on how incorporating new treatment strategies into CLL care pathways may alleviate financial burden for patients and the health care system.
Target audience: Managed care and oncology pharmacists
Type of activity: Application
Release date: November 25, 2024
Expiration date: November 25, 2025
Time to complete activity: 1.5 hours
Learner level: Foundational, Intermediate
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Investigate challenges in current treatment approaches and emerging trends in chronic lymphocytic leukemia (CLL)
- Differentiate the safety profiles for Bruton tyrosine kinase inhibitors as well as monitoring and management strategies to mitigate adverse effects
- Analyze the cost drivers associated with the management of CLL and the value of evolving treatment approaches in lowering the cost of care and health care utilization
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here
